Laboratory biomarkers of delayed cerebral ischemia following subarachnoid hemorrhage: A systematic review
Journal of Circulating Biomarkers · 05.04.2023 · 12 · 17-25
DOI: 10.33393/jcb.2023.2502 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Circulating Biomarkers, online erschienen am 05.04.2023. Verfasst von Maud A Tjerkstra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, University of Amsterdam, Department of Neurosurgery, Neuroscience Amsterdam, Amsterdam, Netherlands. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Delayed cerebral ischemia (DCI) substantially contributes to disability and death in subarachnoid hemorrhage (SAH) patients; however, its pathophysiology is incompletely understood and diagnostic and therapeutic strategies are lacking. Biomarkers may help to elucidate the pathophysiology, optimize early diagnosis, or provide treatment targets. We systematically searched PubMed and Embase on October 13, 2021, for studies that evaluated at least one laboratory biomarker in patients with DCI, using the most up-to-date definition of DCI as proposed by a panel of experts in 2010. Quality of studies was assessed using the Newcastle-Ottawa Scale or Cochrane Collaboration’s risk of bias assessment tool. Biomarkers of clinical and radiological DCI were analyzed separately. Results were meta-analyzed if possible, otherwise narratively reviewed. Biomarkers were classified as significant, inconclusive, or nonsignificant. We defined validated biomarkers as those with significant results in meta-analyses, or in at least two studies using similar methodologies within the same time interval after SAH. The search yielded 209 articles with 724 different biomarkers; 166 studies evaluated 646 biomarkers of clinical DCI, of which 141 were significant and 7 were validated biomarkers (haptoglobulin 2-1 and 2-2, ADAMTS13, vWF, NLR, P-selectin, F2-isoprostane); 78 studies evaluated 165 biomarkers of radiological DCI, of which 63 were significant and 1 was a validated biomarker (LPR). Hence, this review provides a selection of seven biomarkers of clinical DCI and one biomarker of radiological DCI as most promising biomarkers of DCI. Future research should focus on determining the exact predictive, diagnostic, and therapeutic potentials of these biomarkers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Amsterdam UMC, University of Amsterdam, Department of Neurosurgery, Neuroscience Amsterdam, Amsterdam, Netherlands.
- Medical Library, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Amsterdam, Netherlands.
- Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
- Amsterdam UMC, University of Amsterdam, Department of Neurology, Neuroscience Amsterdam, Amsterdam, Netherlands.
Zitieren
APA
Tjerkstra, M. A., Labib, H., Coert, B. A., Spijker, R., Coutinho, J. M., Vandertop, W. P., & Verbaan, D. (2023). Laboratory biomarkers of delayed cerebral ischemia following subarachnoid hemorrhage: A systematic review. Journal of Circulating Biomarkers, 12, 17-25. https://doi.org/10.33393/jcb.2023.2502
Vancouver
Tjerkstra MA, Labib H, Coert BA, Spijker R, Coutinho JM, Vandertop WP, et al. Laboratory biomarkers of delayed cerebral ischemia following subarachnoid hemorrhage: A systematic review. Journal of Circulating Biomarkers. 2023;12:17-25. doi:10.33393/jcb.2023.2502
BibTeX
@article{Tjerkstra2023,
author = {Tjerkstra, Maud A and Labib, Homeyra and Coert, Bert A and Spijker, René and Coutinho, Jonathan M and Vandertop, W Peter and Verbaan, Dagmar},
title = {Laboratory biomarkers of delayed cerebral ischemia following subarachnoid hemorrhage: A systematic review},
journal = {Journal of Circulating Biomarkers},
year = {2023},
volume = {12},
pages = {17--25},
doi = {10.33393/jcb.2023.2502}
}
EUVIMED